WINSTON SALEM, N.C. – Targacept (Nasdaq: TRGT) reported net income of $2.5 million in the third quarter Thursday, nearly double the $1.3 million of a year ago.

The biopharmaceutical firm recognized $18.3 million of a $200 million upfront payment from drug development partner AstraZeneca in January.

Targacept and AstraZeneca are working on a compound that could treat major depressive disorder.

The company also has numerous other products under development.

For the earnings report and an update of Targacept’s various drug programs,

Get the latest news alerts: at Twitter.